Commonwealth Equity Services
PPBT

Commonwealth Equity Services’s Purple Biotech PPBT Stock Holding History

Commonwealth Equity Services’s Portfolio PPBT Stock Details PPBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5
Closed -$11K – 3112
2020
Q2 		$11K Buy
+5
New +$4.91K ﹤0.01% 2930

Other funds holding PPBT

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
ECM
ETrade Capital Management Arlington, Virginia $5.37B AUM 10.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFC
Bedel Financial Consulting Indianapolis, Indiana $888M AUM 19.91% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TPWA
TRUE Private Wealth Advisors Salem, Oregon $1.16B AUM 36.18% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Commonwealth Equity Services's PPBT Position: Q3 2020 in Review

Commonwealth Equity Services sold out of Purple Biotech (PPBT) in Q3 2020, closing a stake of 5 shares — an estimated $11K sold.

Commonwealth Equity Services first reported a position in PPBT in Q2 2020 and held it in 1 quarter. The position peaked at $11K in Q2 2020. 15 funds tracked by Wall St. Rank hold PPBT as of Q3 2020.

  • Commonwealth Equity Services reported no remaining Purple Biotech position as of Q3 2020 after selling out during the quarter.
  • Commonwealth Equity Services sold 5 Purple Biotech shares in Q3 2020, an estimated $11K.
  • Commonwealth Equity Services first reported a position in Purple Biotech in Q2 2020 and held it in 1 quarter.
  • Commonwealth Equity Services's Purple Biotech position peaked at $11K in Q2 2020.
  • 15 funds tracked by Wall St. Rank held Purple Biotech as of Q3 2020.

Based on Commonwealth Equity Services's 13F filing for Q3 2020, filed 5 Nov 2020.